ACT Genomics Receives CAP Accreditation, Offering full-scale and Comprehensive Clinical Services to Transform Cancer Care

2016-04-18 12:00 1393

TAIPEI, April 18, 2016 /PRNewswire/ -- ACT Genomics, an integrated cancer molecular information company offering clinical services for cancer prevention, early detection, treatment selection and disease monitoring through its comprehensive clinical programs, has announced that the company received accreditation from the College of American Pathologists.

Dr. Hua-Chien Chen, the CEO said, "ACT Genomics has been dedicated to international standards of operational performance from day one, and the commitment has been realized through our clinical laboratory certification process." Dr. Shu Jen Chen, the chief scientific officer, commented: "CAP certification for NGS-based tumor profiling service is the key to enable us to accept and report on clinical samples to healthcare professionals around the globe and collaborate with international biopharma partners as we scale for full clinical launch, we are proud to be the first commercial service provider of NGS-based cancer genomics aggressively seeking CAP accreditation in Taiwan."

Aside from the quality assurance progress, ACT Genomics has recently commercialized two advanced NGS-based clinical services, ACTImmune™ and ACTMonitor™ to become the full integrated cancer genomics company. ACTImmune™ offers a unique opportunity to characterize mutation burden and neo-antigen load, which are recently shown as the critical molecular determinants linked to the clinical response of immune-checkpoint inhibitors, anti-PD-1/ anti-PD-L1 agents. ACTMonitor™ utilizes circulating tumor DNA as a liquid biopsy to profile mutation burden in cancer recurrence, and characterize resistant-mutations associated with treatment responses through routine checks for all patients with solid tumors.

ACT Genomics provides comprehensive precision cancer care programs, to address clinical challenges from different stages of cancer care, including cancer prevention, early detection, treatment selection and disease monitoring. With advanced high content sequencing platform, coupling with proprietary bioinformatics engines for clinical reporting, ACT Genomics is committed to meet the highest standard of quality, bring the sound science to the community we serve, and partner with cancer health care professionals to transform cancer care.

ACT Genomics Contact:
Tel: +886-2-2795-3660

To view the original version on PR Newswire, visit:

Source: ACT Genomics